Antifibrotic therapy (AFT) slows disease progression in patients with idiopathic pulmonary
fibrosis (IPF). The Gender-Age-Physiology (GAP) index, was developed based on data at …

Background To examine the relationship between body mass index (BMI) and mortality in
patients with idiopathic pulmonary fibrosis (IPF). Methods We studied a cohort of patients …

Background The processes that result in progression of idiopathic pulmonary fibrosis (IPF)
remain enigmatic. Moreover, the course of this disease can be highly variable and difficult to …

Objective There is a paucity of observational data on antifibrotic therapy for idiopathic
pulmonary fibrosis (IPF). We aimed to assess the course of disease of IPF patients with and …

Introduction Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic
interstitial pneumonias. It is a serious and progressive lung disease with a median survival …

Background: Literature focusing on nutritional variables and survival in interstitial lung
disease (ILD) is limited by its focus on weight and BMI and has not considered body …

Background Idiopathic pulmonary fibrosis (IPF) is relentless progressive interstitial lung
disease. Evaluating predictor of mortality for IPF patients is crucial. The aim of this study was …

Aim of the study: Potential care implications of antifibrotic reimbursement restrictions were
studied by forced vital capacity (FVC) decline, mortality and specialty care related healthcare …

Rationale Longitudinal data on the impact of continued, switched or discontinued antifibrotic
therapy in patients with idiopathic pulmonary fibrosis (IPF) who have disease progression is …

Background Idiopathic pulmonary fibrosis (IPF) is a rare and serious disease characterized
by progressive lung-function loss. Limited evidence has been published on the impact of …